The Medicines Patent Pool and Voluntary Licensing Explained

Medicines are often protected by patents, which grant the developing company a temporary legal monopoly to manufacture and sell the product. While this system rewards pharmaceutical innovation, it can also keep prices high and restrict access to treatments in low- and middle-income countries. Voluntary licensing is a mechanism used to bridge this gap. Through organisations like the Medicines Patent Pool (MPP), patent holders can voluntarily share their intellectual property with generic manufacturers, allowing them to produce and sell more affordable versions of vital medicines in specific markets.

The generics ecosystem relies on a delicate balance of innovation, legal rights, and manufacturing capacity. When patents prevent generic competition, a single manufacturer controls the market. Voluntary licensing disrupts this monopoly legally and predictably, benefiting public health initiatives worldwide by enabling multiple producers to supply the same medicine simultaneously.

How Voluntary Licensing Works

A voluntary licence is a legal agreement where a patent holder permits another party to manufacture and sell a patented medicine. When managed through a patent pool, the patent holder grants a licence to the pool, which then offers sub-licences to multiple generic manufacturers. This setup simplifies what would otherwise be complex, bilateral legal negotiations between originator companies and generic firms. In exchange for the licence, generic companies may pay a small royalty to the patent holder, but they gain the legal certainty needed to invest in production.

By allowing several manufacturers to enter the market at the same time, a competitive environment is created. This competition generally drives prices down significantly. It is important to distinguish voluntary licensing from compulsory licensing, which is when a government forces a patent holder to license a medicine without their consent, typically during a public health emergency. Voluntary licensing is a collaborative, market-based approach that achieves similar price reductions without the need for government intervention.

The Role of the Medicines Patent Pool

Founded in 2010 with support from Unitaid, the MPP is a public health organisation that acts as a neutral intermediary. It initially focused on paediatric and adult HIV medicines, playing a significant role in expanding access to antiretroviral therapy across the developing world. Over time, its mandate expanded to include treatments for tuberculosis, hepatitis C, and, more recently, COVID-19 therapeutics and long-acting health technologies.

By centralising intellectual property rights, the MPP reduces transaction costs for both originator companies and generic firms. The organisation also facilitates the transfer of technology and know-how, which is often necessary when generic manufacturers need to replicate complex formulations, such as fixed-dose combination tablets. This ensures that generic medicines are not only legally permitted but also technically sound and bioequivalent to the originator product.

Impact on Access and the Generics Ecosystem

The primary advantage of voluntary licensing is improved access to affordable medicines. When multiple generic manufacturers can legally produce a drug, market competition typically lowers the cost. This dynamic is vital for public health programmes that rely on the WHO Essential Medicines List (WHO EML) to procure treatments at scale. The availability of affordable generics allows health systems to treat more patients within limited budgets.

For countries like South Africa, which face high burdens of HIV and tuberculosis, the availability of affordable generics is crucial for national treatment programmes. Once these generic medicines are registered with regulators such as the South African Health Products Regulatory Authority (SAHPRA), consumers and healthcare professionals can use tools like HealthSA to look up their registration status and compare the Single Exit Price (SEP) against originator brands, directly observing the financial impact of generic competition.

Limitations and the Global Landscape

Despite its successes, the voluntary licensing model has limitations. Participation by pharmaceutical companies is entirely optional, meaning critical medicines may remain excluded from the pool if the patent holder chooses not to participate. Furthermore, voluntary licences often define specific geographic territories. While they generally include low-income countries, middle-income countries are sometimes excluded from the agreement, even if they face a high disease burden.

Patent pools are also just one piece of a broader access puzzle. Even when a voluntary licence is in place, generic manufacturers must still navigate regulatory approval processes, establish quality standards compliant with Good Manufacturing Practice (GMP), and overcome local supply chain challenges to ensure the medicine reaches the patients who need it. Voluntary licensing is a powerful tool, but it works best when supported by robust regulatory systems and transparent procurement processes.